NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$17.73 -0.35 (-1.94 %)
(As of 05/22/2018 05:40 AM ET)
Previous Close$18.08
Today's Range$17.68 - $18.20
52-Week Range$12.89 - $19.94
Volume1.02 million shs
Average Volume1.55 million shs
Market Capitalization$2.75 billion
P/E Ratio-19.06
Dividend YieldN/A
Beta1.07

About Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Debt-to-Equity Ratio-21.52
Current Ratio4.42
Quick Ratio4.40

Price-To-Earnings

Trailing P/E Ratio-19.06
Forward P/E Ratio-28.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$298.28 million
Price / Sales9.03
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book253.29

Profitability

EPS (Most Recent Fiscal Year)($0.93)
Net Income$-116,930,000.00
Net Margins-34.12%
Return on Equity-2,073.20%
Return on Assets-20.90%

Miscellaneous

Employees730
Outstanding Shares151,940,000

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.06. The biotechnology company had revenue of $69.16 million for the quarter, compared to the consensus estimate of $78.65 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The firm's revenue for the quarter was up 32.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

What price target have analysts set for IRWD?

10 brokers have issued 12 month price objectives for Ironwood Pharmaceuticals' stock. Their forecasts range from $13.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $18.60 in the next year. View Analyst Ratings for Ironwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 54)
  • Dr. Mark G. Currie, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 63)
  • Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 48)
  • Mr. Thomas A. McCourt, Sr. VP of Marketing & Sales and Chief Commercial Officer (Age 61)
  • Mr. Brian M. Cali Ph.D., Co-Founder and Sr. VP of R&D Strategy & External Innovation

Has Ironwood Pharmaceuticals been receiving favorable news coverage?

Headlines about IRWD stock have trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.13 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (3.65%), OppenheimerFunds Inc. (1.70%), Northern Trust Corp (1.03%), Loomis Sayles & Co. L P (1.01%), Sector Gamma AS (0.74%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Which major investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Artal Group S.A., State of Wisconsin Investment Board, Barclays PLC, Sector Gamma AS, Loomis Sayles & Co. L P, California Public Employees Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie and Peter M Hecht. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Which major investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, OppenheimerFunds Inc., UBS Group AG, Engineers Gate Manager LP, Point72 Asset Management L.P., Trexquant Investment LP, Schwab Charles Investment Management Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $17.73.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $2.75 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (IRWD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  316 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  714
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Ironwood Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.60, suggesting that the stock has a possible upside of 4.91%. The high price target for IRWD is $25.00 and the low price target for IRWD is $13.00. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.272.302.272.50
Ratings Breakdown: 2 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.60$18.1250$17.5556$18.2857
Price Target Upside: 4.91% upside2.00% upside15.50% upside22.56% upside

Ironwood Pharmaceuticals (NASDAQ:IRWD) Consensus Price Target History

Price Target History for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Morgan StanleyDowngradeEqual ➝ WeightMediumView Rating Details
5/2/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00LowView Rating Details
5/2/2018MizuhoUpgradeNeutral ➝ Buy$16.00 ➝ $24.00MediumView Rating Details
4/19/2018Berenberg BankInitiated CoverageBuy$25.00MediumView Rating Details
4/9/2018Wells FargoSet Price TargetBuy$18.00HighView Rating Details
1/5/2018Bank of AmericaDowngradeBuy ➝ Underperform$20.00 ➝ $15.00HighView Rating Details
11/27/2017Credit Suisse GroupInitiated CoverageBuy$19.00MediumView Rating Details
8/21/2017CowenSet Price TargetBuy$20.00MediumView Rating Details
7/21/2017Wood & CompanyDowngradeOverweight ➝ NeutralLowView Rating Details
7/21/2017JPMorgan ChaseReiterated RatingOverweight ➝ Neutral$20.00 ➝ $19.00HighView Rating Details
6/16/2017WedbushReiterated RatingNeutral$13.00LowView Rating Details
3/13/2017BTIG ResearchReiterated RatingBuy$18.00 ➝ $21.00LowView Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 ➝ $17.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 ➝ $14.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Ironwood Pharmaceuticals (NASDAQ:IRWD) Earnings History and Estimates Chart

Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ:IRWD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181($0.04)($0.04)($0.04)

Ironwood Pharmaceuticals (NASDAQ IRWD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.21)N/AView Earnings Details
5/1/2018Q1 2018($0.21)($0.27)$78.65 million$69.16 millionViewN/AView Earnings Details
2/15/2018Q4 2017($0.18)($0.14)$88.86 million$94.20 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.2470)($0.18)$73.59 million$86.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.23)($0.28)$70.00 million$65.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.19)($0.33)$69.39 million$52.16 millionViewListenView Earnings Details
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewListenView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.45)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.13)($0.12)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.19)($0.16)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.19)($0.18)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.17)($0.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ironwood Pharmaceuticals (NASDAQ:IRWD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.63%
Insider Trading History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2018Julie MchughDirectorSell1,500$14.06$21,090.0077,908View SEC Filing  
2/21/2018Gina ConsylmanCFOSell3,594$14.66$52,688.0459,125View SEC Filing  
2/21/2018Mark G CurrieInsiderSell1,634$14.66$23,954.4418,124View SEC Filing  
1/24/2018Mark G CurrieInsiderSell60,000$15.45$927,000.00835,000View SEC Filing  
12/7/2017Peter M HechtCEOSell113,405$15.12$1,714,683.604,696,917View SEC Filing  
12/4/2017Julie MchughDirectorSell1,500$16.45$24,675.0079,408View SEC Filing  
11/10/2017Gina ConsylmanCFOSell864$15.20$13,132.80View SEC Filing  
9/5/2017Julie MchughDirectorSell1,500$16.16$24,240.0080,908View SEC Filing  
8/18/2017Gina ConsylmanInsiderSell207$14.34$2,968.3852,865View SEC Filing  
6/22/2017Halley E GilbertInsiderSell35,000$19.75$691,250.0035,000View SEC Filing  
5/15/2017Thomas A MccourtInsiderSell30,000$18.20$546,000.0030,000View SEC Filing  
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.7537,385View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.294,703,315View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.0026,105View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.0029,305View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.7821,123View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.0032,505View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.255,865View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.004,710,322View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.0011,031View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00144,006View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.006,330View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.6225,558View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.505,137View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.0013,231View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.2515,431View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.002,166View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.002,166View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.002,166View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.132,915View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ironwood Pharmaceuticals (NASDAQ IRWD) News Headlines

Source:
DateHeadline
Wall Street Baffled Why Activist Sarissa Went Silent on IronwoodWall Street Baffled Why Activist Sarissa Went Silent on Ironwood
finance.yahoo.com - May 21 at 4:42 PM
Ironwood Pharmaceuticals (IRWD) Given Consensus Recommendation of "Hold" by BrokeragesIronwood Pharmaceuticals (IRWD) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 20 at 5:43 AM
Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director NomineesIronwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees
finance.yahoo.com - May 14 at 9:42 AM
Ironwood Pharmaceuticals (IRWD) Downgraded by ValuEngineIronwood Pharmaceuticals (IRWD) Downgraded by ValuEngine
www.americanbankingnews.com - May 10 at 9:09 PM
Todays Research Reports on Trending Tickers: Horizon Pharma and Ironwood PharmaceuticalsToday's Research Reports on Trending Tickers: Horizon Pharma and Ironwood Pharmaceuticals
finance.yahoo.com - May 10 at 9:17 AM
Morgan Stanley Lowers Ironwood Pharmaceuticals (IRWD) to WeightMorgan Stanley Lowers Ironwood Pharmaceuticals (IRWD) to Weight
www.americanbankingnews.com - May 9 at 6:39 PM
Ironwood Pharmaceuticals (IRWD) Rating Reiterated by Morgan StanleyIronwood Pharmaceuticals (IRWD) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - May 9 at 4:59 PM
Ironwood Pharma to separate R&D and commercial ops into two companies; shares down 8%Ironwood Pharma to separate R&D and commercial ops into two companies; shares down 8%
seekingalpha.com - May 9 at 4:50 PM
Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder ValueIronwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value
finance.yahoo.com - May 9 at 9:09 AM
Ironwood Pharma (IRWD) , Allergan (AGN) Announce Settlement with Aurobindo Pharma Resolving LINZESS Patent LitigationIronwood Pharma (IRWD) , Allergan (AGN) Announce Settlement with Aurobindo Pharma Resolving LINZESS Patent Litigation
www.streetinsider.com - May 4 at 9:00 AM
Ironwood Pharmaceuticals (IRWD) Raised to Buy at ValuEngineIronwood Pharmaceuticals (IRWD) Raised to Buy at ValuEngine
www.americanbankingnews.com - May 4 at 12:17 AM
Ironwood Pharmaceuticals (IRWD) PT Set at $20.00 by BarclaysIronwood Pharmaceuticals (IRWD) PT Set at $20.00 by Barclays
www.americanbankingnews.com - May 3 at 11:43 PM
Ironwood slams Denners bid for board seat as proxy fight loomsIronwood slams Denner's bid for board seat as proxy fight looms
www.bizjournals.com - May 2 at 4:51 PM
Edited Transcript of IRWD earnings conference call or presentation 1-May-18 12:30pm GMTEdited Transcript of IRWD earnings conference call or presentation 1-May-18 12:30pm GMT
finance.yahoo.com - May 2 at 4:51 PM
Ironwood Pharmaceuticals (IRWD) Lifted to Buy at MizuhoIronwood Pharmaceuticals (IRWD) Lifted to Buy at Mizuho
www.americanbankingnews.com - May 2 at 11:56 AM
Ironwood: 1Q Earnings SnapshotIronwood: 1Q Earnings Snapshot
www.cnbc.com - May 2 at 9:03 AM
UPDATE: Mizuho Securities Upgrades Ironwood Pharmaceuticals (IRWD) to BuyUPDATE: Mizuho Securities Upgrades Ironwood Pharmaceuticals (IRWD) to Buy
www.streetinsider.com - May 2 at 9:03 AM
Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to ShareholdersIronwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders
finance.yahoo.com - May 2 at 9:03 AM
Ironwood Pharmaceuticals (IRWD) CEO Peter Hecht on Q1 2018 Results - Earnings Call TranscriptIronwood Pharmaceuticals' (IRWD) CEO Peter Hecht on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 1 at 4:40 PM
Ironwood Pharmaceuticals (IRWD) Announces  Earnings Results, Misses Estimates By $0.06 EPSIronwood Pharmaceuticals (IRWD) Announces Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 1 at 4:14 PM
Ironwood Pharma may satisfy activist Denner with split-up plan, but he still wants a board seatIronwood Pharma may satisfy activist Denner with split-up plan, but he still wants a board seat
www.cnbc.com - May 1 at 3:31 PM
Ironwood Pharmaceuticals (IRWD) Upgraded to "Hold" at Zacks Investment ResearchIronwood Pharmaceuticals (IRWD) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 1 at 12:26 PM
Ironwood Pharmaceuticals Provides First Quarter 2018 Investor UpdateIronwood Pharmaceuticals Provides First Quarter 2018 Investor Update
www.bizjournals.com - May 1 at 9:08 AM
Ironwood Pharmaceuticals misses by $0.04, misses on revenueIronwood Pharmaceuticals misses by $0.04, misses on revenue
seekingalpha.com - May 1 at 9:08 AM
Ironwood Pharmaceuticals (IRWD) to Release Quarterly Earnings on MondayIronwood Pharmaceuticals (IRWD) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 4:28 AM
Ironwood Pharmaceuticals (IRWD) Given Consensus Rating of "Hold" by BrokeragesIronwood Pharmaceuticals (IRWD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 25 at 5:36 AM
Ironwood Pharmaceuticals Target of Unusually High Options Trading (IRWD)Ironwood Pharmaceuticals Target of Unusually High Options Trading (IRWD)
www.americanbankingnews.com - April 24 at 7:00 AM
Ironwood Pharmaceuticals (IRWD) Earns Buy Rating from Analysts at Berenberg BankIronwood Pharmaceuticals (IRWD) Earns Buy Rating from Analysts at Berenberg Bank
www.americanbankingnews.com - April 19 at 3:36 PM
Ironwood Pharmaceuticals (IRWD) Lowered to "Sell" at Zacks Investment ResearchIronwood Pharmaceuticals (IRWD) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM
Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update CallIronwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call
finance.yahoo.com - April 17 at 5:12 PM
Ironwood Pharmaceuticals (IRWD) Lowered to "Hold" at BidaskClubIronwood Pharmaceuticals (IRWD) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 8:07 PM
Ironwood Pharmaceuticals (IRWD) Cut to Sell at ValuEngineIronwood Pharmaceuticals (IRWD) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM
Ironwood Pharmaceuticals (IRWD) Downgraded to "Strong Sell" at BidaskClubIronwood Pharmaceuticals (IRWD) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - April 11 at 9:30 PM
Ironwood Pharmaceuticals Sees Unusually Large Options Volume (IRWD)Ironwood Pharmaceuticals Sees Unusually Large Options Volume (IRWD)
www.americanbankingnews.com - April 11 at 7:04 AM
Activist investor Denner targets Cambridge’s Ironwood, lifting sharesActivist investor Denner targets Cambridge’s Ironwood, lifting shares
www.bizjournals.com - April 10 at 4:47 PM
Ironwood Pharmaceuticals (IRWD) Upgraded at ValuEngineIronwood Pharmaceuticals (IRWD) Upgraded at ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM
Ironwood Pharma (IRWD) Announces Director Nomination from Sarissa CapitalIronwood Pharma (IRWD) Announces Director Nomination from Sarissa Capital
www.streetinsider.com - April 9 at 4:43 PM
Ironwood investor Sarissa Capital to nominate board memberIronwood investor Sarissa Capital to nominate board member
seekingalpha.com - April 9 at 4:43 PM
Ironwood Pharmaceuticals (IRWD) Given a $18.00 Price Target by Wells Fargo AnalystsIronwood Pharmaceuticals (IRWD) Given a $18.00 Price Target by Wells Fargo Analysts
www.americanbankingnews.com - April 9 at 3:30 PM
Ironwood Pharmaceuticals Announces Director Nomination from Sarissa CapitalIronwood Pharmaceuticals Announces Director Nomination from Sarissa Capital
finance.yahoo.com - April 9 at 9:15 AM
Ironwood Pharmaceuticals (IRWD) Lowered to "Sell" at ValuEngineIronwood Pharmaceuticals (IRWD) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 11:49 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Given Consensus Recommendation of "Hold" by AnalystsIronwood Pharmaceuticals, Inc. (IRWD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 31 at 5:36 AM
Ironwood Pharmaceuticals (IRWD) Cut to "Sell" at Zacks Investment ResearchIronwood Pharmaceuticals (IRWD) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:49 PM
Ironwood Pharmaceuticals Sees Unusually High Options Volume (IRWD)Ironwood Pharmaceuticals Sees Unusually High Options Volume (IRWD)
www.americanbankingnews.com - March 28 at 7:22 AM
Ironwood Pharmaceuticals (IRWD) Upgraded to Buy by BidaskClubIronwood Pharmaceuticals (IRWD) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
Ironwood Pharmaceuticals (IRWD) Downgraded by BidaskClubIronwood Pharmaceuticals (IRWD) Downgraded by BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM
Ironwood Pharmaceuticals (IRWD) Presents At Barclays Global Healthcare Conference 2018 - SlideshowIronwood Pharmaceuticals (IRWD) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 9:16 AM
Ironwood Pharmaceuticals (IRWD) Presents At 38th Annual Cowen and Company Healthcare Conference - SlideshowIronwood Pharmaceuticals (IRWD) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 12 at 5:50 PM
Short Interest in Ironwood Pharmaceuticals, Inc. (IRWD) Grows By 7.6%Short Interest in Ironwood Pharmaceuticals, Inc. (IRWD) Grows By 7.6%
www.americanbankingnews.com - March 11 at 1:58 AM
Head to Head Analysis: Ironwood Pharmaceuticals (IRWD) & Senomyx (SNMX)Head to Head Analysis: Ironwood Pharmaceuticals (IRWD) & Senomyx (SNMX)
www.americanbankingnews.com - March 8 at 5:24 AM

SEC Filings

Ironwood Pharmaceuticals (NASDAQ:IRWD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ironwood Pharmaceuticals (NASDAQ:IRWD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ironwood Pharmaceuticals (NASDAQ IRWD) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.